The Latest Breaking News from Eli Lilly

Drugs helping weight-loss like Novo Nordisk's Wegovy and Eli Lilly's Mounjaro drove blockbuster sales for the pharma giants in the third quarter.

The market roared higher again Thursday, but the jobs report looms large. Apple warned on holiday sales.

Eli Lilly stock rose early Thursday after diabetes blockbuster Mounjaro helped the company beat sales expectations.

December S&P 500 futures (ESZ23) are up +0.50%, and December Nasdaq 100 E-Mini futures (NQZ23) are up +0.70% this morning as market participants weighed the possible peak of the Federal Reserve’s historic tightening campaign and looked ahead to an earnings report from Apple.

Techs led futures higher, with Palantir and Roku among the big earnings winners. Fed chief Jerome Powell signaled no more rate hikes, fueling Wednesday's strong market rally.

Lilly will pay $250 million to Beam for the rights to three gene-editing drugs from Verve. VERV stock and Beam stock skyrocketed.

The good times keep rolling for Novo Nordisk and its weight-loss drugs. But it's bad news for some medical device stocks.

The Chart of the Day belongs to the pharmaceutical giant Eli Lilly (LLY) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the Flipchart...

Don't assume that all S&P 500 stocks are struggling. A small group are actually thriving, thank you.

Powell said he is encouraged by the slowing trend in inflation but would not rule out more rate hikes.

Eli Lilly stock has crushed the broader markets in the past 10 years. But should you buy LLY at current levels, given its lofty valuation?